CLINICAL TRIALS AND OBSERVATIONS Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
نویسندگان
چکیده
1Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy; 2Centre Régional de Traitement de l’Hémophilie, Hôpital Edouard Herriot, University Claude Bernard, Lyon, France; 3Haemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Vivantes Hospital, Berlin, Germany; 4Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; 5Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University of Vienna, Wien, Austria; 6Clinical Research and Development, CSL Behring, King of Prussia, PA; and 7Centro Emofilia, Azienda Ospedaliera Careggi, Florence, Italy
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
Human plasma–derived factor IX (pdFIX) concentrates are routinely used to treat patients with hemophilia B, an X-linked bleeding disorder that affects 1 in 30 000 males, but concerns remain regarding transmission of blood-borne pathogens. Therefore, the safety and efficacy of recombinant human factor IX (rFIX) were evaluated. A 20-center international trial was conducted in previously treated p...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Current factor VIII (FVIII) products display a half-life (t1/2) of 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain of human IgG1 to extend circulating rFVIII t1/2. This first-in-human study in previously treated sub...
متن کاملPlenary Paper CLINICAL TRIALS AND OBSERVATIONS Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A Johnny Mahlangu, Jerry S. Powell, Margaret V. Ragni, Pratima Chowdary, Neil C. Josephson, Ingrid Pabinger, Hideji Hanabusa, Naresh Gupta, Roshni Kulkarni, Patrick Fogarty, David Perry, Amy Shapiro, K. John Pasi, Shashikant Apte, Ivan Nestorov, Haiyan Jiang, Shuanglian Li, Srividya Neelakantan, Lynda M. Cristiano, ...
متن کاملSustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
The successful prophylactic treatment of hemophilia A by frequent infusions of plasma concentrates or recombinant factor VIII (hFVIII) indicates that gene therapy may be a potential alternative for the treatment of the disease. For efficient delivery and long-term expression of the hFVIII gene, a novel minimal adenovirus (mini-Ad) vector, MiniAdFVIII, has been developed. The vector is devoid of...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study
1Van Creveldkliniek, University Medical Center Utrecht, the Netherlands; 2Department of Pediatrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands; 3Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; 4Prof Hess-Kinderklinik, Zentrum fur Kinderheilkunde und Jugendmedizin, Bremen, Germany; 5Centre of Pediatr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2012